Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:uu-280259" > Long-term immunogen...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Chlibek, RomanUniv Def, Fac Mil Hlth Sci, Hradec Kralove, Czech Republic. (author)

Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults

Article/chapterEnglish2016

Publisher, publication year, extent ...

Elsevier BV,2016
electronicrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-280259
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-280259URI
https://doi.org/10.1016/j.vaccine.2015.09.073DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Background: An investigational subunit vaccine containing the varicella-zoster virus (VZV) glycoprotein E (gE) and the AS01(B) adjuvant system is being evaluated for the prevention of herpes zoster (HZ) in older adults. A phase II trial evaluating different formulations of this vaccine (containing 25 mu g, 50 mu g, or 100 mu g gE) was conducted in adults >= 60 years of age and showed that all formulations elicited robust cellular and humoral immune responses for up to 3 years after vaccination. In this follow-up study in subjects who received two doses of the 50 mu g gE/AS01(B) formulation (HZ/su), we assessed the persistence of the immune responses for up to 6 years after vaccination. Methods: This phase II, open-label, multicenter, single-group trial conducted in the Czech Republic, Germany, Sweden, and the Netherlands followed 129 subjects who had received two doses (2 months apart) of HZ/su during the initial trial. Vaccine-induced immune responses (frequencies of gE-specific CD4(+) T cells expressing >= 2 activation markers and serum anti-gE antibody concentrations) were evaluated at 48, 60, and 72 months after the first HZ/su dose. Results: Six years after vaccination with HZ/su, gE-specific cell-mediated immune responses and anti-gE antibody concentrations had decreased by 20-25% from month 36, but remained higher than the prevaccination values. At month 72, the gE-specific cell-mediated immune response was 3.8 times higher than the prevaccination value (477.3 vs. 119.4 activated gE-specific CD4(+) T cells per 10(6) cells), and the anti-gE antibody concentration was 7.3 times higher than the prevaccination value (8159.0 vs. 1121.3 mIU/mL). No vaccine-related serious adverse events were reported between months 36 and 72. Conclusions: gE-specific cellular and humoral immune responses persisted for 6 years after two-dose vaccination with HZ/su in healthy older adults. No safety concerns were identified.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper Immunologi inom det medicinska området hsv//swe
MEDICAL AND HEALTH SCIENCES Basic Medicine Immunology in the medical area hsv//eng
Varicella-zoster virus
Glycoprotein E
Subunit vaccine
lmmunogenicity
Persistence

Added entries (persons, corporate bodies, meetings, titles ...)

Pauksens, KarlisUppsala universitet,Infektionssjukdomar(Swepub:uu)karlpauk (author)
Rombo, LarsUppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Univ Hosp, Dept Med, Stockholm, Sweden.(Swepub:uu)larra728 (author)
van Rijckevorsel, GiniPubl Hlth Serv Amsterdam, Dept Infect Dis, Amsterdam, Netherlands. (author)
Richardus, Jan H.Municipal Publ Hlth Serv Rotterdam Rijnmond, Rotterdam, Netherlands. (author)
Plassmann, GeorgUnterfrintroper Hausarztzentrum, Essen, Germany. (author)
Schwarz, Tino F.Stiftung juliusspital, Cent Lab, Wurzburg, Germany.;Stiftung juliusspital, Vaccinat Ctr, Wurzburg, Germany. (author)
Catteau, GregoryGSK Vaccines, Wavre, Belgium. (author)
Lal, HimalGSK Vaccines, King Of Prussia, PA USA. (author)
Heineman, Thomas C.GSK Vaccines, King Of Prussia, PA USA. (author)
Univ Def, Fac Mil Hlth Sci, Hradec Kralove, Czech Republic.Infektionssjukdomar (creator_code:org_t)

Related titles

In:Vaccine: Elsevier BV34:6, s. 863-8680264-410X1873-2518

Internet link

Find in a library

Vaccine (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Chlibek, Roman; Pauksens, Karlis; Rombo, Lars; van Rijckevorsel ...; Richardus, Jan H ...; Plassmann, Georg; show more...; Schwarz, Tino F.; Catteau, Gregory; Lal, Himal; Heineman, Thomas ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Basic Medicine; and Immunology in th ...

Articles in the publication: Vaccine

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se